Skip to main content
All Posts By

Clinic Hours

FDA approves daxibotulinumtoxinA-lanm injection for glabellar lines

The US FDA has approved daxibotulinumtoxinA-lanm injection (Daxxify) to temporarily improve the appearance of moderate to severe glabellar lines (frown lines) in adults.

Action: It’s an acetylcholine release inhibitor and neuromuscular blocking agent, is the first peptide-formulated, long-acting neuromodulator approved for this indication.

Adverse effects: headache (6%), eyelid ptosis (2%), and facial paresis, including facial asymmetry (1%).

Contraindicated in adults with hypersensitivity to any botulinum toxin preparation.

Conjunctival papilloma case

History: A healthy 10-year-old boy had a 12 months history of an itchy right eye with frequent tearing. Small masses that gradually developed in the right caruncula lacrimal area and multifocal small nodules with papillomatous growth and vascular fronds.

What’s the diagnosis?

1. Chalazion
2. Papilloma
3. Pterygium
4. Pinguecula
5. Coloboma

Answer: Conjunctival papilloma is an acquired benign epithelial tumor of the conjunctiva and may manifest as a sessile or pedunculated conjunctival mass.

Cause: Human papillomavirus (HPV) 6 and HPV 11

Signs:

  • This lesion is typically benign.
  • It is seen commonly in older adults.
  • Anatomically, the lesion commonly occurs at the limbus or the bulbar conjunctiva.
  • These lesions may spread centrally toward the cornea or laterally toward the conjunctiva.
  • Visual acuity may be affected if the lesion grows centrally.
  • These lesions almost always are unilateral and single.
  • They tend to have variable proliferation potential with a tendency to slowly enlarge in size.

Differential diagnosis: Ichthyosis, Sebaceous Gland Carcinoma, Conjunctival Squamous Cell Carcinoma

Treatment: Surgical excision, Erilesional cryotherapy, intralesional or topical interferon-α injection, carbon dioxide (CO2) laser, topical mitomycin-C (MMC), and oral cimetidine have been reported to be adjunctive treatments. Recurrences are not uncommon.

Reference: AAO, NEJM
Clinical Rounds by ClinicHours

Blue Fugates case

The Fugates, a family who lived in the hills of Kentucky, commonly known as the “Blue Fugates” or the “Blue People of Kentucky”, are notable for having been carriers of a genetic trait that led to methemoglobinemia, which causes the appearance of blue-tinged skin.

Martin Fugate and Elizabeth Smith who had married and settled near Hazard, Kentucky, around 1820, were both carriers of the recessive methemoglobinemia (met-H) gene. As a result, four of their seven children exhibited blue skin, and continued progenation within the very limited local gene pool ensured that many descendants of the Fugates were born with met-H.

A hematologist Madison Cawein treated the family with methylene blue, which eased their symptoms and reduced the blue coloring of their skin.

Reason: The underlying mechanism involves some of the iron in hemoglobin is converted from the ferrous [Fe2+] to the ferric [Fe3+] form.

Signs and symptoms: (methemoglobin level above 10%) include shortness of breath, cyanosis, mental status changes (~50%), headache, fatigue, exercise intolerance, dizziness, and loss of consciousness. People with severe methemoglobinemia (methemoglobin level above 50%) may exhibit seizures, coma, and death (level above 70%).

Causes:

  1. Genetic: Due to a deficiency of the enzyme diaphorase I (cytochrome b5 reductase), Hereditary met-Hb, HbM, or HbH.
  2. Acquired: Drugs – trimethoprim, sulfonamides, and dapsone, local anesthetics especially articaine, benzocaine, prilocaine, lidocaine, and aniline dyes, metoclopramide, rasburicase, umbellulone, chlorates, bromates, and nitrites.

Differential diagnosis: Argyria, sulfhemoglobinemia, heart failure

Treatment: Supplemental oxygen and methylene blue given as a 1% solution (10 mg/ml) 1 to 2 mg/kg administered IV slowly over five minutes.

Note: The image shown above is of Mr. Paul Karason who consumed silver as a home remedy for severe dermatitis and later on developed argyria.

FDA approves first gene therapy for Beta-Thalassemia

The US FDA has approved the gene therapy betibeglogene autotemcel (Zynteglo) for adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. Functional copies of the mutated gene are inserted into patient’s hematopoietic stem cells via a replication-defective lentivirus. A one-time gene therapy cost $2.8 million. Adverse events such as abdominal pain, hot flush, dyspnea, tachycardia, noncardiac chest pain, and cytopenias were noted.

A novel Langya virus infects 35 people in eastern China

A novel zoonotic RNA Langya virus (LayV) is a henipavirus first detected in the China provinces of Shandong and Henan. The name of the virus refers to Mt. Langya.

Symptoms: fever, fatigue, cough

Langya henipavirus affects humans, dogs, goats, and its presumed original host are shrews.

Lab findings in patients: thrombocytopenia, leukopenia, impaired liver and kidney function test.

Treatment: No specific drug or vaccination only supportive care.

Monkeypox : Signs, Symptoms & Treatment

Monkeypox is a zoonotic orthopoxvirus.

Usual onset: 5–21 days post-exposure.

Duration: 2 to 4 weeks.

Route: Human-to-human transmission, exposure to infected body fluids or contaminated objects by small droplets through the airborne route.

Symptoms: Fever, headache, muscle pains, shivering, mostly nonitchy blistering rash on face, hands, soles and swollen lymph nodes.

Complications: Secondary infections, eye infection, visual loss, scarring, encephalitis, sepsis, bronchopneumonia.

Types: Central African (Congo Basin), West African

Diagnosis: Testing for viral DNA PCR

Differential diagnosis: Chickenpox, smallpox

Prevention: Smallpox vaccine, hand washing, covering rash, PPE

Treatment: Supportive, antivirals, vaccinia immune globulin

Medication: Tecovirimat

Leukemia cutis case

History: A 50-year-old woman presented with asymptomatic multiple cutaneous nodules all over the body of 4 months duration. Cutaneous examination showed multiple hyperpigmented nodules and plaques involving face, trunk, and extremities. Peripheral smear showed abnormally elevated leucocyte count (TLC-70,000) with abnormal cells: myeloblasts 40%, promyelocytes 8% and myelocytes 39%. Auer rods were present in few myeloblasts. What is the most likely diagnosis?

  1. Gottron’s papules
  2. Guttate psoriasis
  3. Immune thrombocytopenia purpura (ITP)
  4. Leukemia cutis
  5. Solar purpura

Answer:

Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the epidermis, the dermis, or the subcutis, resulting in clinically identifiable cutaneous lesions. Leukemia cutis may follow, precede or occur concomitantly with the diagnosis of systemic leukemia.

The clinical appearance of leukemia cutis is variable with erythematous to violaceous papules or nodules being the most frequent lesions (60%), followed by infiltrated plaques, generalised cutaneous eruption and erythroderma. They are frequently asymptomatic. The nodules are typically firm or rubbery in consistency, and can become purpuric if the patient is thrombocytopenic.

Source: PMC
Clinical Rounds by ClinicHours

FDA approves Crizotinib for Myofibroblastic Tumors

The US FDA approves crizotinib (Xalkori) for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT) in adults and children over 1 year of age.

Crizotinib is a selective tyrosine kinase inhibitor currently approved for the treatment of metastatic non-small cell lung cancer in patients whose tumors are positive for ALK or ROS1 as detected by an FDA-approved test, and for ALD-positive anaplastic large cell lymphoma.

Adverse reactions occurring in 35% or more pediatric patients included vomiting, nausea, diarrhea, abdominal pain, rash, vision disorder, upper respiratory tract infection, cough, pyrexia, musculoskeletal pain, fatigue, edema, constipation, and headache.

Source: Medscape

Eruptive xanthomas case

History: A 30 yr old obese man presents with an asymptomatic rash on his back, arms, and hands that had developed 2 week earlier. On physical examination, scattered pink-yellow papules were present on the upper back, extensor surfaces of the upper arms, and dorsa of the hands. A fasting blood sample was grossly lipemic. Which of the following is the most likely diagnosis?

  1. Eruptive xanthomas
  2. Sebaceous hyperplasia
  3. Granuloma annulare
  4. Molluscum contagiosum

Answer: Eruptive xanthomas typically present as crops of 2–5 mm yellow papules with a red rim over extensor surfaces such as the buttocks or shoulders, but can be widespread including inside the mouth. The papules may be tender and are usually itchy. They may demonstrate köbnerisation. Eruptive xanthomas are due to hypertriglyceridaemia (triglyceride >11.2 mmol/L) of any cause.

Source: Dermanetz

Dabrafenib Trametinib approved for metastatic tumors with BRAF V600E mutation

The US FDA has approved dabrafenib + trametinib for adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with the BRAF V600E mutation whose disease has progressed following prior treatment and who have no satisfactory alternative treatment options.

The combination represents “the first and only BRAF/MEK inhibitor to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation, which drives tumor growth in more than 20 different tumor types, and it is the only BRAF/MEK inhibitor approved for use in pediatric patients.

The combination already carries indications for BRAF-mutated melanoma, non–small cell lung cancer, and thyroid cancer. The new approval was based on two adult trials and one pediatric trial that showed an overall response benefit for patients with high- and low-grade gliomas, biliary tract cancers, and certain gynecologic and gastrointestinal cancers.

Source: Medscape
error: